TY - JOUR
T1 - Association of Initial and Longitudinal Changes in C-reactive Protein With the Risk of Cardiovascular Disease, Cancer, and Mortality
AU - Suthahar, Navin
AU - Wang, Dongyu
AU - Aboumsallem, Joseph Pierre
AU - Shi, Canxia
AU - de Wit, Sanne
AU - Liu, Elizabeth E.
AU - Lau, Emily S.
AU - Bakker, Stephan J.L.
AU - Gansevoort, Ron T.
AU - van der Vegt, Bert
AU - Jovani, Manol
AU - Kreger, Bernard E.
AU - Lee Splansky, Greta
AU - Benjamin, Emelia J.
AU - Vasan, Ramachandran S.
AU - Larson, Martin G.
AU - Levy, Daniel
AU - Ho, Jennifer E.
AU - de Boer, Rudolf A.
N1 - Publisher Copyright:
© 2022 The Authors
PY - 2023/4
Y1 - 2023/4
N2 - Objective: To evaluate the value of serial C-reactive protein (CRP) measurements in predicting the risk of cardiovascular disease (CVD), cancer, and mortality. Methods: The analysis was performed using data from two prospective, population-based observational cohorts: the Prevention of Renal and Vascular End-Stage Disease (PREVEND) study and the Framingham Heart Study (FHS). A total of 9253 participants had CRP measurements available at two examinations (PREVEND: 1997-1998 and 2001-2002; FHS Offspring cohort: 1995-1998 and 1998-2001). All CRP measurements were natural log-transformed before analyses. Cardiovascular disease included fatal and nonfatal cardiovascular, cerebrovascular and peripheral vascular events, and heart failure. Cancer included all malignancies except nonmelanoma skin cancers. Results: The mean age of the study population at baseline was 52.4±12.1 years and 51.2% (n=4733) were women. Advanced age, female sex, smoking, body mass index, and total cholesterol were associated with greater increases in CRP levels over time (Pall<.001 in the multivariable model). Baseline CRP, as well as increase in CRP over time (ΔCRP), were associated with incident CVD (hazard ratio [HR]: 1.29 per 1-SD increase; 95% confidence interval [CI]: 1.29 to 1.47, and HR per 1-SD increase: 1.19; 95% CI: 1.09 to 1.29 respectively). Similar findings were observed for incident cancer (baseline CRP, HR: 1.17; 95% CI: 1.09 to 1.26; ΔCRP, HR: 1.08; 95% CI: 1.01 to 1.15) and mortality (baseline CRP, HR: 1.29; 95% CI: 1.21 to 1.37; ΔCRP, HR: 1.10; 95% CI: 1.05 to 1.16). Conclusion: Initial as well as subsequent increases in CRP levels predict future CVD, cancer, and mortality in the general population.
AB - Objective: To evaluate the value of serial C-reactive protein (CRP) measurements in predicting the risk of cardiovascular disease (CVD), cancer, and mortality. Methods: The analysis was performed using data from two prospective, population-based observational cohorts: the Prevention of Renal and Vascular End-Stage Disease (PREVEND) study and the Framingham Heart Study (FHS). A total of 9253 participants had CRP measurements available at two examinations (PREVEND: 1997-1998 and 2001-2002; FHS Offspring cohort: 1995-1998 and 1998-2001). All CRP measurements were natural log-transformed before analyses. Cardiovascular disease included fatal and nonfatal cardiovascular, cerebrovascular and peripheral vascular events, and heart failure. Cancer included all malignancies except nonmelanoma skin cancers. Results: The mean age of the study population at baseline was 52.4±12.1 years and 51.2% (n=4733) were women. Advanced age, female sex, smoking, body mass index, and total cholesterol were associated with greater increases in CRP levels over time (Pall<.001 in the multivariable model). Baseline CRP, as well as increase in CRP over time (ΔCRP), were associated with incident CVD (hazard ratio [HR]: 1.29 per 1-SD increase; 95% confidence interval [CI]: 1.29 to 1.47, and HR per 1-SD increase: 1.19; 95% CI: 1.09 to 1.29 respectively). Similar findings were observed for incident cancer (baseline CRP, HR: 1.17; 95% CI: 1.09 to 1.26; ΔCRP, HR: 1.08; 95% CI: 1.01 to 1.15) and mortality (baseline CRP, HR: 1.29; 95% CI: 1.21 to 1.37; ΔCRP, HR: 1.10; 95% CI: 1.05 to 1.16). Conclusion: Initial as well as subsequent increases in CRP levels predict future CVD, cancer, and mortality in the general population.
UR - http://www.scopus.com/inward/record.url?scp=85151365481&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85151365481&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2022.10.013
DO - 10.1016/j.mayocp.2022.10.013
M3 - Article
C2 - 37019514
AN - SCOPUS:85151365481
SN - 0025-6196
VL - 98
SP - 549
EP - 558
JO - Mayo Clinic Proceedings
JF - Mayo Clinic Proceedings
IS - 4
ER -